Marilyn Glassberg, MD
Pulmonary Disease · Maywood, ILNPI 1033146782
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $127,868 of the $170,177 with a category attached, or 75.1%. 19 manufacturers reported payments, led by Boehringer Ingelheim at 54.4% of the total. Reporting peaked in 2019 at $80,742 and has fallen 66.3% since, to $27,194 in 2025. Among pulmonary disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $1215.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$93K
- Genentech USA, Inc.$24K
- F. Hoffmann-la Roche AG$11K
- Boehringer Ingelheim International GmbH$10K
- E.r. Squibb & Sons, L.L.C.$9K
- United Therapeutics Corporation$6K
- plus $17K from 13 others
Across 81 payments — averaging $10,603 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$477K
- Eli Lilly$78K
- Boehringer Ingelheim$73K
- Regeneron$57K
- Novartis$49K
- Celularity Inc.$42K
- plus $82K from 8 others
What the payments were for
- Consulting fees$127,86875%
- Speaking & faculty fees$28,57317%
- Travel & lodging$9,9376%
- Food & beverage$3,7982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 69 | $92,621 |
| Genentech USA, Inc. | 22 | $23,853 |
| F. Hoffmann-la Roche AG | 4 | $11,159 |
| Boehringer Ingelheim International GmbH | 7 | $9,703 |
| E.r. Squibb & Sons, L.L.C. | 8 | $9,400 |
| United Therapeutics Corporation | 4 | $5,986 |
| Esperion Therapeutics, Inc. | 2 | $5,700 |
| Actelion Pharmaceuticals, Ltd | 1 | $4,500 |
| AbbVie | 1 | $4,025 |
| Boehringer Ingelheim Canada Ltd.ltee | 1 | $2,250 |
| Genentech, Inc. | 5 | $455 |
| Atricure, Inc. | 2 | $204 |
| Amgen | 5 | $156 |
| Johnson & Johnson(2 entities) | 4 | $71 |
| PTC Therapeutics, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Insmed, Inc. | 1 | $16 |
| Electromed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$170,177 in reported general payments places this provider in the 95th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Maywood
- Bradford BemissMaywood$259K
- Matthew NobariMaywood$209K
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.